DRL continues to generate free cash flows (FCFs) due to strongholds in some legacy drugs. Its lower valuation compared to its peers and str...

Valuations are at multi-year lows; sector’s expected to remain resilient amid current downturn.

Market succumbed to profit booking as investors turned cautious ahead of election outcome.

Metal packs have been the single biggest drivers of Nifty earnings for the quarter, says Khemka

In two cases - Dr Reddy's and Strides Shasun -promoter stakes have increased marginally.

The stock suffered a fall immediately after the announcement of results but recovered to close with a gain of 3.65% at Rs 2,973.85 on BSE.

Most global brokerage firms maintained a positive view on the stock post March quarter results and CLSA has even raised its 12-month target...

Sensex plunged over 800 points on Thursday tracking weak cues from other Asian and European markets and weak earnings by leading index cons...

The Nifty ended at 8,808.90, down 143 points or 1.60 per cent. It touched an all-time high of 8,996.60 and a low of 8,775.10 in trade today.

The stock has been weak since the beginning of December. The slide has aggravated as Russia’s rouble slipped to an all-time low.

Sensex slipped over 150 points after RBI announced a status quo. The index pared some losses soon after, but is now down over 100 points.

Dr Reddy's stock slipped 1.11% to close at Rs 3,046 on the Bombay Stock Exchange on Wednesday as the results fell short of street expectati...

The company reported sales of Rs 3,587 crore in the second quarter, 7% more than a year earlier, while net profit slipped 17% to Rs 574 cro...

Tracking the momentum, Nifty also slipped below its crucial psychological level of 7700, weighed down by losses in realty, banks, pharma an...

Dr Reddy's Labs (DRL) is going to be major outperformer in the pharma pack, thanks to its recent drug launches in the US market.

The pharma sector is likely to maintain a healthy revenue growth rate of 20-25% for the quarter ended December 2011.

Dr Reddy’s Laboratories (DRL) suffered a 68% fall in Q4 net profit ended March 2008, after writing down the intangible value of the product...